Plain-English translation of NCT07053345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depressive Disorder, Treatment-Resistant research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing esketamine nasal spray for people with treatment-resistant depression — a form of depression that hasn't improved despite trying at least two standard antidepressant medications. Esketamine is a medication that works differently than traditional antidepressants, and researchers want to see if it can help reduce depressive symptoms over a 4-week period.
Many people with depression don't respond well to standard antidepressants, and they need new treatment options. This trial is studying whether the medication can offer relief for those whose depression has been difficult to treat.
You likely qualify if…
You likely don't qualify if…
You would self-administer the nasal spray twice a week for 4 weeks. Each dose involves spraying the medication into each nostril — either one spray per nostril (56 mg dose) or three quick sprays per nostril delivered in succession (84 mg dose). The dose may be adjusted based on how you respond and tolerate the treatment. Researchers will measure your depressive symptoms at the start and end of the 4-week period to see if the medication helps.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
South Korea